Femasys (FEMY) Registration filing summary

Company overview and business model

• Focuses on women's health with a portfolio of in-office therapeutic and diagnostic products addressing infertility, permanent birth control, and cancer diagnosis.

• Products are FDA-cleared and approved in multiple global markets, with ongoing commercialization in the U.S. and internationally.

• Key products include FemaSeed (infertility treatment), FemBloc (non-surgical permanent birth control), FemVue (diagnostic), and FemCerv (cancer diagnosis).

• Holds over 200 issued patents globally and maintains in-house manufacturing and development capabilities.

• Targets multi-billion dollar global market segments with little recent innovation.

Financial performance and metrics

• As of June 30, 2025, cash and cash equivalents were $3.2 million, projected to increase to $10.4 million post-offering.

• Net tangible book value per share as of June 30, 2025, was $0.04; post-offering, it is expected to rise to $0.20 per share.

• Immediate dilution to new investors is estimated at $0.50 per share based on the assumed offering price.

• Gross proceeds from a May 2025 offering were $4.5 million.

• The company has recurring losses, negative cash flows, and a net accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Use of proceeds and capital allocation

• Estimated net proceeds of $7.2 million will be used for product development, general corporate purposes, capital expenditures, working capital, and administrative expenses.

• Management has broad discretion over the allocation of proceeds.

• May use a portion of proceeds for acquisitions or investments in complementary businesses, though no current plans exist.